The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Platinum as an active pharmaceutical ingredient is a key innovation area in pharmaceutical

Platinum-based drugs are widely used for the treatment of cancer. Various emerging technologies such as dendrimers, polymers, liposomes, nanotubes, nano-formulations, and combination studies show promise for the safe delivery of platinum-based compounds and help to eliminate unwanted side-effects. Apart from cancer, various platinum-based compounds are being investigated for diseases, primarily in CNS, immunology, respiratory and ENT disorders.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 240 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of platinum as active pharmaceutical ingredient.

Key players in platinum as active pharmaceutical ingredient – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local.’

Patent volumes related to platinum as active pharmaceutical ingredient

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Vertex Pharmaceuticals 223 Unlock Company Profile
F. Hoffmann-La Roche 213 Unlock Company Profile
Bristol-Myers Squibb 210 Unlock Company Profile
Otsuka Holdings 208 Unlock Company Profile
E. Merck 151 Unlock Company Profile
Amgen 120 Unlock Company Profile
Pharma Mar 119 Unlock Company Profile
Pierre Fabre Foundation 92 Unlock Company Profile
Eagle Pharmaceuticals 71 Unlock Company Profile
Regeneron Pharmaceuticals 67 Unlock Company Profile
Ipsen 66 Unlock Company Profile
Johnson & Johnson 65 Unlock Company Profile
Esteve Pharmaceuticals 62 Unlock Company Profile
Arcus Biosciences 61 Unlock Company Profile
C. H. Boehringer Sohn 61 Unlock Company Profile
Pfizer 59 Unlock Company Profile
Eli Lilly and 59 Unlock Company Profile
AbbVie 59 Unlock Company Profile
Spectrum Pharmaceuticals 58 Unlock Company Profile
Novartis 58 Unlock Company Profile
Mayo Clinic 56 Unlock Company Profile
GSK 53 Unlock Company Profile
Bayer 52 Unlock Company Profile
Astellas Pharma 46 Unlock Company Profile
Takeda Pharmaceutical 46 Unlock Company Profile
Sprint Bioscience 45 Unlock Company Profile
Merck & Co 42 Unlock Company Profile
Superlab Far East 41 Unlock Company Profile
United Nations Industrial Development Organization 41 Unlock Company Profile
Ono Pharmaceutical 39 Unlock Company Profile
Polaris Pharmaceutical Group 39 Unlock Company Profile
Komipharm International 35 Unlock Company Profile
Saniona 32 Unlock Company Profile
Gilead Sciences 32 Unlock Company Profile
Cavion 32 Unlock Company Profile
Aslan Pharmaceuticals 31 Unlock Company Profile
Hanmi Science 30 Unlock Company Profile
Corcept Therapeutics 30 Unlock Company Profile
MEI Pharma 30 Unlock Company Profile
Zymeworks 30 Unlock Company Profile
Bio-Bedst 30 Unlock Company Profile
Mayne Pharma Group 30 Unlock Company Profile
Merrimack Pharmaceuticals 30 Unlock Company Profile
Intensity Therapeutics 29 Unlock Company Profile
Eisai 29 Unlock Company Profile
Enzychem Lifesciences 28 Unlock Company Profile
Help/Systems 28 Unlock Company Profile
RDInnovation 28 Unlock Company Profile
Helperby Therapeutics 26 Unlock Company Profile
Alfasigma 26 Unlock Company Profile

Source: GlobalData Patent Analytics

Vertex Pharmaceuticals is one of the leading patent filers in platinum-based drug therapies. The company has filed several patents involving platinum compounds that target ATR tyrosine kinase and is involved in developing drugs for the treatment of pancreatic cancer and non-small cell lung cancer.

In terms of application diversity, Oncolytics Biotech is the top company, followed by PharmAust and Calgent Biotechnology. By means of geographic reach, Komipharm International holds the top position. Whilst Amgen and Novartis are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.